Yifan Pharmaceutical Co Ltd 2024 SR
The report highlights Yifan Pharmaceutical's 2024 ESG performance, focusing on innovation in oncology, rare diseases, and biologics, with the approval of Ryzneuta in over 30 countries. The company emphasizes green transition through energy-saving upgrades and waste reduction, achieving a 32.6 percent decrease in workshop wastewater volume. It maintains high standards of corporate governance and business ethics, reporting zero significant corruption incidents. Socially, the company invested 3.32 million yuan in public welfare and achieved a 100 percent labor contract signing rate for its 4,098 employees.
Company: Yifan Pharmaceutical Co Ltd
Sector: Health Care
Country: China
Year: 2024
Type: SR
Pages: 50
Yifan Pharmaceutical Co Ltd
ESG Report
The report highlights Yifan Pharmaceutical's 2024 ESG performance, focusing on innovation in oncology, rare diseases, and biologics, with the approval of Ryzneuta in over 30 countries. The company emphasizes green transition through energy-saving upgrades and waste reduction, achieving a 32.6 percent decrease in workshop wastewater volume. It maintains high standards of corporate governance and business ethics, reporting zero significant corruption incidents. Socially, the company invested 3.32 million yuan in public welfare and achieved a 100 percent labor contract signing rate for its 4,098 employees.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees